Moderna, Inc. Earnings Per Share (Diluted)
Moderna, Inc. (MRNA) reported Earnings Per Share (Diluted) of -$1.97 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-31
- Moderna, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.97.
- Moderna, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$3.40.
- Moderna, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$2.11.
- Moderna, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.51, a 1800.00% decline year-over-year.
- Moderna, Inc. earnings per share, diluted for fiscal 2025 was -$7.26.
- Moderna, Inc. earnings per share, diluted for fiscal 2024 was -$9.28.
- Moderna, Inc. earnings per share, diluted for fiscal 2023 was -$12.33, a 161.28% decline from fiscal 2022.
- Moderna, Inc. earnings per share, diluted for fiscal 2022 was $20.12, a 28.88% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.97 10-Q · filed 2026-07-31 | -$5.36 10-Q · filed 2026-07-31 | -$7.47 derived: net income ÷ weighted average shares · filed 2026-07-31 | -$8.00 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2026-03-31 | -$3.40 10-Q · filed 2026-05-01 | -$5.51 derived: net income ÷ weighted average shares · filed 2026-05-01 | -$6.04 derived: net income ÷ weighted average shares · filed 2026-05-01 | -$8.16 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2025-12-31 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$2.62 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$4.75 derived: net income ÷ weighted average shares · filed 2026-07-31 | -$7.26 10-K · filed 2026-02-20 |
| 2025-09-30 | -$0.51 10-Q · filed 2025-11-06 | -$2.63 derived: net income ÷ weighted average shares · filed 2026-07-31 | -$5.15 10-Q · filed 2025-11-06 | -$8.04 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2025-06-30 | -$2.13 10-Q · filed 2026-07-31 | -$4.64 10-Q · filed 2026-07-31 | -$7.53 derived: net income ÷ weighted average shares · filed 2026-07-31 | -$7.44 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2025-03-31 | -$2.52 10-Q · filed 2026-05-01 | -$5.41 derived: net income ÷ weighted average shares · filed 2026-05-01 | -$5.32 derived: net income ÷ weighted average shares · filed 2026-05-01 | -$8.63 derived: net income ÷ weighted average shares · filed 2026-05-01 |
| 2024-12-31 | -$2.89 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$2.82 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$6.12 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$9.28 10-K · filed 2026-02-20 |
| 2024-09-30 | $0.03 10-Q · filed 2025-11-06 | -$3.23 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$6.37 10-Q · filed 2025-11-06 | -$5.75 derived: net income ÷ weighted average shares · filed 2026-02-20 |
| 2024-06-30 | -$3.33 10-Q · filed 2025-08-01 | -$6.41 10-Q · filed 2025-08-01 | -$5.85 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$15.35 derived: net income ÷ weighted average shares · filed 2026-02-20 |
| 2024-03-31 | -$3.07 10-Q · filed 2025-05-01 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$12.02 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$15.64 derived: net income ÷ weighted average shares · filed 2026-02-20 |
| 2023-12-31 | $0.57 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$8.95 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$12.57 derived: net income ÷ weighted average shares · filed 2026-02-20 | -$12.33 10-K · filed 2026-02-20 |
| 2023-09-30 | -$9.53 10-Q · filed 2024-11-07 | -$13.15 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$12.89 10-Q · filed 2024-11-07 | -$8.81 derived: net income ÷ weighted average shares · filed 2025-02-21 |
| 2023-06-30 | -$3.62 10-Q · filed 2024-08-01 | -$3.39 10-Q · filed 2024-08-01 | $0.41 derived: net income ÷ weighted average shares · filed 2025-02-21 | $3.01 derived: net income ÷ weighted average shares · filed 2025-02-21 |
| 2023-03-31 | $0.19 10-Q · filed 2024-05-02 | $3.80 derived: net income ÷ weighted average shares · filed 2025-02-21 | $6.34 derived: net income ÷ weighted average shares · filed 2025-02-21 | $11.65 derived: net income ÷ weighted average shares · filed 2025-02-21 |
| 2022-12-31 | $3.60 derived: net income ÷ weighted average shares · filed 2025-02-21 | $6.12 derived: net income ÷ weighted average shares · filed 2025-02-21 | $11.40 derived: net income ÷ weighted average shares · filed 2025-02-21 | $20.12 10-K · filed 2025-02-21 |
| 2022-09-30 | $2.53 10-Q · filed 2023-11-03 | $7.80 derived: net income ÷ weighted average shares · filed 2023-11-03 | $16.46 10-Q · filed 2023-11-03 | $27.88 derived: net income ÷ weighted average shares · filed 2024-02-23 |
| 2022-06-30 | $5.24 10-Q · filed 2023-08-03 | $13.85 10-Q · filed 2023-08-03 | $25.21 derived: net income ÷ weighted average shares · filed 2024-02-23 | $32.88 derived: net income ÷ weighted average shares · filed 2024-02-23 |
| 2022-03-31 | $8.58 10-Q · filed 2023-05-04 | $19.89 derived: net income ÷ weighted average shares · filed 2024-02-23 | $27.56 derived: net income ÷ weighted average shares · filed 2024-02-23 | $34.00 derived: net income ÷ weighted average shares · filed 2024-02-23 |
| 2021-12-31 | $11.29 derived: net income ÷ weighted average shares · filed 2024-02-23 | $18.96 derived: net income ÷ weighted average shares · filed 2024-02-23 | $25.42 derived: net income ÷ weighted average shares · filed 2024-02-23 | $28.29 10-K · filed 2024-02-23 |
| 2021-09-30 | $7.70 10-Q · filed 2022-11-03 | $14.13 derived: net income ÷ weighted average shares · filed 2022-11-03 | $17.00 10-Q · filed 2022-11-03 | $16.70 derived: net income ÷ weighted average shares · filed 2023-02-24 |
| 2021-06-30 | $6.46 10-Q · filed 2022-08-03 | $9.30 10-Q · filed 2022-08-03 | $8.90 derived: net income ÷ weighted average shares · filed 2023-02-24 | $8.46 derived: net income ÷ weighted average shares · filed 2023-02-24 |
| 2021-03-31 | $2.84 10-Q · filed 2022-05-04 | $2.30 derived: net income ÷ weighted average shares · filed 2023-02-24 | $1.76 derived: net income ÷ weighted average shares · filed 2023-02-24 | $1.49 derived: net income ÷ weighted average shares · filed 2023-02-24 |
| 2020-12-31 | -$0.69 derived: net income ÷ weighted average shares · filed 2023-02-24 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-02-24 | -$1.59 derived: net income ÷ weighted average shares · filed 2023-02-24 | -$1.96 10-K · filed 2023-02-24 |
| 2020-09-30 | -$0.59 10-Q · filed 2021-11-04 | -$0.90 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.26 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$0.31 10-Q · filed 2021-08-05 | -$0.66 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$0.35 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$1.55 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |